U.S. markets open in 7 hours 5 minutes

Omega Therapeutics, Inc. (OMGA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.96-0.43 (-1.92%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close22.39
Open22.12
Bid0.00 x 900
Ask0.00 x 1400
Day's Range20.42 - 23.94
52 Week Range15.50 - 24.29
Volume943,632
Avg. Volume169,057
Market Cap1.049B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.06
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Omega Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/04/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • PR Newswire

    Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives

    Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the second quarter ended June 30, 2021.

  • PR Newswire

    Omega Therapeutics Announces Pricing of Initial Public Offering

    Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross pr